-
Mashup Score: 5
BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the lifting of the clinical hold and clearance of its
Source: ir.vervetx.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
The expanded approval now includes patients with comorbidities who have not yet had a first cardiovascular event.
Source: MPRCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Leqvio approval expanded to include patients with comorbidities who have not yet had a first cardiovascular event. #HeFH #ASCVD https://t.co/xR6ctjU3NA
-
-
Mashup Score: 4Coronary Artery Calcium among Patients with Heterozygous Familial Hypercholesterolemia - 12 month(s) ago
AbstractAims. We aimed to determine if coronary artery calcium (CAC) is associated with cardiovascular disease (CVD) events, defined as CVD-related death, unsta
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#CAC among Patients with #HeFH https://t.co/IoccV0Dvoa
-
-
Mashup Score: 1
Purpose During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical trials with alirocumab. This post hoc analysis evaluated the differences in physician–patient dosing…
Source: SpringerLinkCategories: Cardiologists, Latest HeadlinesTweet-
Perception of the severity of #HeFH : big disparities. #Alirocumab #PCSK9i https://t.co/DXDHVNtXmD
-
-
Mashup Score: 17Statin Recommendations for Primary Prevention - 2 year(s) ago
In 2016, the US Preventive Services Task Force (USPSTF) issued its first recommendations for statin therapy for the primary prevention of cardiovascular disease based on an evidence review that included 19 randomized clinical trials (RCTs).1 In this issue of JAMA, the USPSTF presents an update2 of…
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
Statin Recommendations for Primary Prevention: More of the Same or Time for a Change? “The earlier the better” as highlights by #HeFH patients #lipids https://t.co/UUECN5RZ0k
-
-
Mashup Score: 3
1. Mach F., Baigent C., Catapano A.L., et al. “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk”. Eur Heart J 2020;41:111-188. 2. Elbers L.P., Kastelein J.J., Sjouke B. “Thyroid hormone mimetics: the past, current status and future challenges”. Curr Atheroscler Rep 2016;18:14. 3. Kelly M.J., Pietranico-Cole S., Larigan J.D., et al….
Categories: Expert Picks, Latest HeadlinesTweet-
New study of #resmetirom (THR-β agonist) use in #HeFH, while receiving statin-based lipid lowering therapy, was associated with significant LDL drops: https://t.co/CkQEvJGnZf #JACC #ASCVD #CardioTwitter https://t.co/pJczWgSSht
-
-
Mashup Score: 5FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year - 2 year(s) ago
Novartis today announced the US Food and Drug Administration (FDA) approval of Leqvio® (inclisiran)
Source: MultiVuCategories: Cardiology News and Journals, Latest HeadlinesTweet-
FDA approves Leqvio (#inclisiran), indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical #ASCVD or #HeFH who require additional lowering of LDL-C. Learn more from @Novartis: https://t.co/JOciY7idvd https://t.co/iffxuZwPVP
-
-
Mashup Score: 1
Heterozygous familial hypercholesterolemia (HeFH) results in significant elevations in LDL-C and premature atherosclerotic cardiovascular disease (ASCVD). Current guidelines recommend add-on proprotein subtilisin/kexin type 9 inhibitor (PCSK9i) therapy for additional LDL-C lowering beyond statins. D …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: Perceptions and #Barriers on the Use of #PCSK9i in #HeFH https://t.co/2hU508ifoG
-
-
Mashup Score: 2
The approval is based on 24- and 80-week findings showing significant benefit in LDL-C reduction with the subcutaneous injection drug.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
The #FDA has approved evolocumab (Repatha) injection as an add-on therapy with diet or other treatment for patients aged ≥10 years with #HeFH and #HoFH. #RareDisease https://t.co/YEsDDtmdux
-
-
Mashup Score: 0
A global call to action on FH To find details of the National Lead Investigators and central contributing clinic for your country, go to the contact list >> EAS FHSC Mission Statement The mission of the EAS-FHSC is to empower the medical & global community to seek changes in their respective countries or organizations regarding how…
Source: www.eas-society.orgCategories: Cardiologists, Latest HeadlinesTweet-
The EAS-FH Studies Collaboration (FHSC) #EAS #lipids #FH #HeFH https://t.co/yeEys9FbSx
-
Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in #HeFH https://t.co/mJeucuXvfM